PURE Bioscience, Inc. (PURE)

PURE Bioscience Income Statement

Financials in millions USD. Fiscal year is August - July.

Year	2023	2022	2021	2020	2019
Revenue	1.88	1.85	3.93	6.92	1.91
Revenue Growth (YoY)	1.30%	-52.81%	-43.23%	262.34%	7.61%
Cost of Revenue	0.91	0.85	1.85	2.9	0.73
Gross Profit	0.97	1	2.08	4.02	1.18
Selling, General & Admin	4.3	4.11	4.05	3.7	6.42
Research & Development	0.3	0.32	0.34	0.32	0.35
Other Operating Expenses	-0	0	-0	0.01	0
Operating Expenses	4.6	4.43	4.39	4.02	6.77
Operating Income	-3.94	-3.43	-2.31	0.01	-5.59
Interest Income	0.01	0.01	0	0.01	0.01
Interest Expense	0.01	0.01	0	0.01	0.01
Other Expense / Income	0.01	0.07	0.01	0.01	0.97
Pretax Income	-3.96	-3.49	-2.32	0	-6.55
Income Tax	0.01	0.01	0	0.01	0.01
Net Income	-3.96	-3.5	-2.32	-0.01	-6.56
Shares Outstanding (Basic)	111	89	87	82	73
Shares Outstanding (Diluted)	111	89	87	85	73
Shares Change	25.41%	1.91%	3.03%	16.10%	8.33%
EPS (Basic)	-0.04	-0.04	-0.03	-0.00	-0.09
EPS (Diluted)	-0.04	-0.04	-0.03	-0.00	-0.09
Free Cash Flow	-3.31	-2.5	-1.69	0.61	-3
Free Cash Flow Per Share	-0.03	-0.03	-0.02	0.01	-0.04
Gross Margin	51.73%	53.97%	52.84%	58.13%	61.86%
Operating Margin	-210.07%	-184.84%	-58.85%	0.13%	-292.77%
Profit Margin	-211.03%	-188.72%	-59.05%	-0.09%	-343.69%
Free Cash Flow Margin	-176.40%	-134.86%	-42.98%	8.83%	-157.31%
Effective Tax Rate	-	-	-	250.00%	-
EBITDA	-3.52	-3.21	-2.14	0.2	-5.35
EBITDA Margin	-187.27%	-173.34%	-54.57%	2.91%	-280.09%
Depreciation & Amortization	0.12	0.21	0.17	0.19	0.24
EBIT	-3.63	-3.43	-2.32	0.01	-5.59
EBIT Margin	-193.50%	-184.84%	-58.95%	0.13%	-292.72%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.